Use of biologics for the management of Crohn's disease: IG-IBD technical review based on the GRADE methodology

被引：2
|
作者：
Bonovas, Stefanos [1 ,2 ]
Piovani, Daniele [1 ,2 ]
Pansieri, Claudia [1 ,2 ]
Macaluso, Fabio Salvatore [3 ]
Orlando, Ambrogio [3 ]
Festa, Stefano [4 ]
Papi, Claudio [4 ]
Pugliese, Daniela [5 ]
Armuzzi, Alessandro [1 ,6 ]
机构：
[1] Humanitas Univ, Dept Biomed Sci, Via R Levi Montalcini 4, I-20072 Milan, Italy
[2] IRCCS Humanitas Res Hosp, Milan, Italy
[3] Villa Sofia Cervello Hosp, IBD Unit, Palermo, Italy
[4] San Filippo Neri Hosp, IBD Unit, Rome, Italy
[5] Policlin Univ A Gemelli IRCCS Fdn, Dept Med & Surg Sci, Div Internal Med & Gastroenterol, Rome, Italy
[6] IRCCS Humanitas Res Hosp, IBD Ctr, Milan, Italy
来源：
DIGESTIVE AND LIVER DISEASE | 2023年 / 55卷 / 06期
关键词：
Crohn's disease; Guidelines; GRADE; MAINTENANCE THERAPY; INFLIXIMAB MAINTENANCE; JAPANESE PATIENTS; ADALIMUMAB; INDUCTION; METAANALYSIS; USTEKINUMAB; VEDOLIZUMAB; REMISSION; AZATHIOPRINE;
D O I：
10.1016/j.dld.2023.02.019
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
The therapeutic armamentarium for the management of Crohn's disease (CD) is rapidly expanding. Sev-eral biologic therapies (e.g. infliximab, adalimumab, vedolizumab, and ustekinumab) have been regulatory approved, and there is considerable practice variability in the treatment of patients with CD. This technical review systematically searched and identified the current evidence, synthesized it using meta-analytic methodology, appraised its quality, and concisely presented it, thus forming the basis for developing clinical practice recommendations on the use of biologic treatments in adult patients with CD. (c) 2023 The Author(s). Published by Elsevier Ltd on behalf of Editrice Gastroenterologica Italiana S.r.l.
引用
收藏
页码：695 / 703
页数：9
相关论文
共 50 条
  • [21] Diagnostic interobserver variability in Crohn’s disease- and ulcerative colitis-associated dysplasia: a multicenter digital survey from the IG-IBD Pathologists Group
    G. Leoncini
    F. Donato
    L. Reggiani-Bonetti
    T. Salviato
    M. Cadei
    M. Daperno
    M. B. Principi
    A. Armuzzi
    F. Caprioli
    G. Canavese
    V. Villanacci
    Techniques in Coloproctology, 2021, 25 : 101 - 108
  • [22] Diagnostic interobserver variability in Crohn's disease- and ulcerative colitis-associated dysplasia: a multicenter digital survey from the IG-IBD Pathologists Group
    Leoncini, G.
    Donato, F.
    Reggiani-Bonetti, L.
    Salviato, T.
    Cadei, M.
    Daperno, M.
    Principi, M. B.
    Armuzzi, A.
    Caprioli, F.
    Canavese, G.
    Villanacci, V.
    TECHNIQUES IN COLOPROCTOLOGY, 2021, 25 (01) : 101 - 108
  • [23] A review and expert opinion of the use of certolizumab for Crohn's disease
    Evans, Ashley T.
    Lee, Scott D.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2012, 12 (03) : 363 - 370
  • [24] A review of the therapeutic management of Crohn's disease
    Kumar, Aditi
    Cole, Alexander
    Segal, Jonathan
    Smith, Philip
    Limdi, Jimmy K.
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2022, 15
  • [25] Biologics in Focus: A Comprehensive Review of Current Biological and Small Molecules Therapies for Crohn's Disease in the United Arab Emirates (UAE)
    Alrubaiy, Laith
    Pitsillides, Louise Christine
    O'Connor, Thomas
    Woodhill, Matilda
    Higgins, Harry
    Swaid, Thaer Khaleel
    Alkhader, Doa'a
    Koutoubi, Zaher
    GASTROINTESTINAL DISORDERS, 2024, 6 (03): : 644 - 660
  • [26] IBD LIVE Case Series-Case 2: Previous Cancer in a Patient with Crohn's Disease: Is It Appropriate to Use Biologics and Immunosuppressants for IBD Treatment?
    Le, Peter N.
    Greer, Julia B.
    Oikonomou, Ioannis
    Schraut, Wolfgang H.
    Siegel, Corey A.
    Cross, Raymond K.
    Holubar, Stefan D.
    Tinsley, Andrew
    Koltun, Walter A.
    Binion, David G.
    Regueiro, Miguel D.
    INFLAMMATORY BOWEL DISEASES, 2015, 21 (06) : 1401 - 1406
  • [27] RACIAL DIFFERENCES IN USE OF BIOLOGICS FOR CROHN'S DISEASE IN A MEDICAID POPULATION
    Flasar, M.
    Mulani, P. M.
    Yang, M.
    Chao, J.
    Lu, M.
    Cross, R.
    GUT, 2011, 60 : A138 - A138
  • [28] Immune-Mediated Inflammatory Diseases Awareness and Management among Physicians Treating Patients with Inflammatory Bowel Disease: An IG-IBD Survey
    Vernero, Marta
    Bezzio, Cristina
    Ribaldone, Davide G.
    Caprioli, Flavio A.
    Fantini, Massimo C.
    Festa, Stefano
    Macaluso, Fabio S.
    Orlando, Ambrogio
    Pugliese, Daniela
    Renna, Sara
    Rispo, Antonio
    Savarino, Edoardo V.
    Variola, Angela
    Saibeni, Simone
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (07)
  • [29] New biologics in the management of Crohn's disease: focus on certolizumab pegol
    Colombo, Elisabetta
    Bossa, Fabrizio
    Latiano, Anna
    Palmieri, Orazio
    Andriulli, Angelo
    Annese, Vito
    CLINICAL AND EXPERIMENTAL GASTROENTEROLOGY, 2009, 2 : 61 - 68
  • [30] Review article: causative factors and the clinical management of patients with Crohn's disease who lose response to anti-TNF-α therapy
    Danese, S.
    Fiorino, G.
    Reinisch, W.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2011, 34 (01) : 1 - 10
12345